| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Combination immunotherapy with conventional intensive therapy for advanced neuroblastoma is the hopeful new therapy. To establish new intensive multimodal therapeutic regimen, we applied the concept of chemoimmunotherapy. Firstly, we demonstrated that doxorubicin induces immunogenic cell death in vitro. Using died neuroblastoma cell which induced immunogenicity, we successfully generate antigen presenting cell (APC) which can induce antitumor immune reaction, by co-culturing died neuroblastoma cell treated and doxorubicin and bone marrow cell with GM-CSF, IL-4 and CpG-ODN. This APC can promote IFN-g production by CD8a+ lymphocytes in co-culture with doxorubicin treated neuroblastoma cell, and can suppress the progression of intravenously injected neuroblastoma by the induction of antitumor immune reaction in vivo. We analyzed the cell surface antigen expression on this APC and showed that the pattern of cell surface antigen expression is compatible with activated dendritic cells.
|
